Cargando…
An update on clinical trials for chemoprevention of human skin cancer
The pathophysiology of skin cancer is complex, with multiple factors contributing to its development. The proactive treatment of skin cancer has been investigated in the form of chemoprevention of cutaneous malignancies in clinical trials. Chemoprevention is the use of natural or pharmacologic agent...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544834/ https://www.ncbi.nlm.nih.gov/pubmed/37786882 http://dx.doi.org/10.20517/2394-4722.2022.99 |
_version_ | 1785114558000529408 |
---|---|
author | Jiminez, Victoria Yusuf, Nabiha |
author_facet | Jiminez, Victoria Yusuf, Nabiha |
author_sort | Jiminez, Victoria |
collection | PubMed |
description | The pathophysiology of skin cancer is complex, with multiple factors contributing to its development. The proactive treatment of skin cancer has been investigated in the form of chemoprevention of cutaneous malignancies in clinical trials. Chemoprevention is the use of natural or pharmacologic agents that prevent or reverse skin cancer development. Multiple trials have arisen over the past decades to explore the efficacy of specific agents to halt the progression of UV radiation damage. This comprehensive review article aims to assess clinical trials performed with chemopreventive agents for melanoma and nonmelanoma skin cancers. The following compounds were most often used in these trials: nicotinamide, retinoids, polyphenolic antioxidants, COX-2 selective inhibitors, non-steroidal anti-inflammatory drugs, difluoromethylornithine, and 5-fluorouracil. Many agents show promise in their ability to prevent nonmelanoma skin cancer formation, with few melanoma trials demonstrating efficacy. The chemoprevention efforts aimed at skin cancer are complex; current and future trials will be instrumental in identifying therapeutic agents that pose efficacy in halting cancer development and assessing whether long-term administration is tolerable. |
format | Online Article Text |
id | pubmed-10544834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-105448342023-10-02 An update on clinical trials for chemoprevention of human skin cancer Jiminez, Victoria Yusuf, Nabiha J Cancer Metastasis Treat Article The pathophysiology of skin cancer is complex, with multiple factors contributing to its development. The proactive treatment of skin cancer has been investigated in the form of chemoprevention of cutaneous malignancies in clinical trials. Chemoprevention is the use of natural or pharmacologic agents that prevent or reverse skin cancer development. Multiple trials have arisen over the past decades to explore the efficacy of specific agents to halt the progression of UV radiation damage. This comprehensive review article aims to assess clinical trials performed with chemopreventive agents for melanoma and nonmelanoma skin cancers. The following compounds were most often used in these trials: nicotinamide, retinoids, polyphenolic antioxidants, COX-2 selective inhibitors, non-steroidal anti-inflammatory drugs, difluoromethylornithine, and 5-fluorouracil. Many agents show promise in their ability to prevent nonmelanoma skin cancer formation, with few melanoma trials demonstrating efficacy. The chemoprevention efforts aimed at skin cancer are complex; current and future trials will be instrumental in identifying therapeutic agents that pose efficacy in halting cancer development and assessing whether long-term administration is tolerable. 2023 2023-02-27 /pmc/articles/PMC10544834/ /pubmed/37786882 http://dx.doi.org/10.20517/2394-4722.2022.99 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Jiminez, Victoria Yusuf, Nabiha An update on clinical trials for chemoprevention of human skin cancer |
title | An update on clinical trials for chemoprevention of human skin cancer |
title_full | An update on clinical trials for chemoprevention of human skin cancer |
title_fullStr | An update on clinical trials for chemoprevention of human skin cancer |
title_full_unstemmed | An update on clinical trials for chemoprevention of human skin cancer |
title_short | An update on clinical trials for chemoprevention of human skin cancer |
title_sort | update on clinical trials for chemoprevention of human skin cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544834/ https://www.ncbi.nlm.nih.gov/pubmed/37786882 http://dx.doi.org/10.20517/2394-4722.2022.99 |
work_keys_str_mv | AT jiminezvictoria anupdateonclinicaltrialsforchemopreventionofhumanskincancer AT yusufnabiha anupdateonclinicaltrialsforchemopreventionofhumanskincancer AT jiminezvictoria updateonclinicaltrialsforchemopreventionofhumanskincancer AT yusufnabiha updateonclinicaltrialsforchemopreventionofhumanskincancer |